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ABSTRACT
Inflammatory bowel disease is a chronic inflammatory disease that consist of Crohn’s disease and ulcerative 
colitis. A dramatic increase in the prevalence if inflammatory bowel disease (IBD) within developing countries 
including in Asia makes IBD a substantial global medical burden and modern refractory disease, and it is 
imperative that Asian healthcare systems especially physician are aware of this and familiar with the clinical 
manifestation and management. The aim of this case report is to present a case of IBD in young adult in Indonesia. 
Patient came with complaint of chronic diarrhea and had seen multiple doctor without improvement. Inflammatory 
bowel disease should always be considered in patient with chronic diarrhea with or without extraintestinal 
manifestation especially after poor response of usual antidiarrheal medication. Diagnosing of IBD is based on 
clinical manifestation, physical examination, laboratory result and endoscopy. Until now, ileocolonoscopy and 
biopsy is the most accurate diagnostic modality for IBD and can be used to differentiate between ulcerative 
colitis and Crohn’s disease. Treatment of IBD are drugs such as mesalazine until surgery based on the severity 
or complication of disease.
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ABSTRAK
Inflammatory bowel disease (IBD) adalah penyakit kronis yang terdiri dari penyakit Crohn dan kolitis 
ulserativa. Peningkatan dramatis dalam prevalensi dari IBD di negara-negara berkembang termasuk di Asia 
menjadikan IBD sebagai beban medis global yang substansial, dan sangat penting untuk sistem kesehatan Asia 
terutama dokter menyadari hal ini dan mengetahui manifestasi klinis dan manajemen dari IBD. Tujuan dari 
laporan kasus ini adalah untuk menyajikan kasus IBD pada dewasa muda di Indonesia. Pasien datang dengan 
keluhan diare kronis dan telah berobat ke banyak dokter sebelumnya tanpa adanya perbaikan. Inflammatory 
bowel disease harus selalu dipertimbangkan pada pasien dengan diare kronis dengan atau tanpa manifestasi 
ekstraintestinal terutama setelah respon yang buruk dari obat antidiare biasa. Diagnosis IBD didasarkan pada 
manifestasi klinis, pemeriksaan fisik, hasil laboratorium dan endoskopi. Hingga saat ini, ileocolonoskopi dan 
biopsi adalah modalitas diagnostik paling akurat untuk IBD dan dapat digunakan untuk membedakan antara 
kolitis ulserativa dan penyakit Crohn. Tatalaksana IBD adalah dengan obat-obatan seperti mesalazine sampai 
operasi berdasarkan tingkat keparahan atau komplikasi penyakit.
Kata kunci: inflammatory bowel disease, colitis ulseratif, penyakit crohn, diare
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INTRODUCTION 
Inflammatory bowel disease (IBD) is a chronic 
inflammatory disease that involves the gastrointestinal 
tract and resulted from combination of genetic 
susceptibility, environmental exposure and dysregulated 
response to intestinal microbiota with an alternating 
relapsing and remitting clinical progression.1,2 
Inflammatory bowel disease consist of Crohn’s disease 
(CD) and ulcerative colitis (UC).1 Ulcerative colitis 
is restricted to the mucosa of the colon, whereas the 
lesions in CD are often discontinuous, occur across the 
entire wall of the organ (transmural), and involve any 
part of the gastrointestinal tract from mouth to anus.3 
The highest occurrence of IBD is seen in developed 
countries in North America and Europe, affecting up to 
0.5% of the general population.1 Other than developed 
countries, developing countries such as countries in 
Asia has also been experiencing IBD.1 Ng et al state 
that in the past two decades, Asia has been experiencing 
a significant increase in IBD incidence with highest 
prevalence in East and South Asia.1 
In 2012, incidence rate in Indonesia for UC is 
0.55 per 100,000 persons and CD 0.33 per 100,000 
persons. A dramatic increase in the prevalence if IBD 
within developing countries including in Asia makes 
IBD a substantial global medical burden and modern 
refractory disease, and it is imperative that Asian 
healthcare systems especially physician are aware of 
this and familiar with the clinical manifestation and 
management.1,2 The aim of this case report is to present 
a case of IBD in young adult in Indonesia.
CASE ILLUSTRATION
A sixteen year old boy came to the hospital 
with chief complaint of diarrhea for 2 months. The 
characteristic of diarrhea was porridge-like to liquid, 
around 3 to 5 times a day, yellowish, with no blood. 
There was no fever, but patient complaint of epigastric 
pain with slight nausea and no vomiting. He lost his 
appetite and admit to lost 20 kilograms in 2 months. 
He is underweight. He already seen multiple doctors 
beforehand and was diagnosed with gastroenteritis 
and antibiotic, probiotic and anti-diarrhea was given 
but there was no improvement (diarrhea and weight 
loss persist). Around a month before, he complained 
of pain in his perianal region and felt a lump in 
his perianal region. No joint pain, joint swelling, 
erythema or red eyes and blurry vision. There was no 
family history of similar disorder, atopy, drug abuse 
and sexual activity.
At admission, the patient malnourished with 
normal vital sign. Bowel sound was increased with 
no abdominal tenderness. We found perianal abscess. 
Other physical sign were normal.
Laboratory results revealed hemoglobin (Hb) 10.4 
g/dL (13.0-18.0), hematocrit 31.8% (40-54), white 
blood cell (WBC) 14,000/uL (4,000-10,000), platelets 
536,000/uL (150,000-400,000), C-reactive protein 
(CRP) 90.4 mg/L (< 5), erythrocyte sedimentation rate 
(ESR) 54 mm/hour (0-15), mean corpuscular volume 
(MCV) 69.4 fL (81-96), mean corpuscular hemoglobin 
(MCH) 22.7 pg (27-36), mean corpuscular hemoglobin 
concentration (MCHC) 32.1 g/L (31-37), differential 
count 0/0/1/88/10/1, aspartate aminotransferase (AST) 
13 mg/dL (5-34), alanine aminotransferase (ALT) 9 
mg/dL (< 55), albumin 3.1 g/dL (3.5-50.0), creatinine 
0.8 mg/dL (0.7-1.3), serum iron 14 ug/dL (65-175), 
total iron binding capacity (TIBC) 185 ug/dL (71-
504), transferrin saturation 7.6% (15-50), natrium 
134 mmol/L (134-145), kalium 3.6 mmol/L (3.5-5.5), 
chloride 101 mmol/L (97-111), blood glucose 115 mg/
dL (< 200), carcinoembryonic antigen (CEA) 1.16 
ng/mL (0-5.2), FT4 1.29 pmol/L (1.1-1.8), FT3 2,4 
pmol/L (2.6-5.1), fecal calprotectin > 2100 (< 50), 
seramoeba (-), HbsAg (-), anti-HCV (-) with IgM and 
IgG H. pylori (-).
Stool analysis revealed sign of gastrointestinal 
infection with occult blood test positive. Colonoscopy 
showed perianal abscess with internal hemorrhoid 
grade I-II, hyperemia, erosion and superficial ulcers 
in most mucosal parts of rectum to caecum, mucosa 
of ileum terminalis appears normal with conclusion 
of suggestive ulcerative colitis (Figure 1). Colon 
biopsy was performed in several parts and revealed 
irregular superficial epithelium with multiple erosive 
and ulcerative tissue, hyperemic lamina propria with 
multiple chronic and acute inflammatory cells, distorted 
crypts and multiple crypt abscess, which disclosed as 
active chronic colitis with crypt destruction and no 
sign of malignancy. This findings can be found in IBD.
Based on the data above, diagnosis was made, which 
is inflammatory bowel disease (ulcerative colitis), iron 
deficiency anemia and malnutrition. He was then given 
ringer lactate 1500cc/24 hour, levofloxacin 1 x 750 
mg IV, mesalazin 500 mg three times daily orally, 
methylprednisolone 125 mg once daily IV, rebamipide 
100 mg three times daily, PPI two times daily IV,  iron 
supplement 2 times daily orally, folic acid  mg two 
times daily orally, and antiemetic. Parenteral nutrition 
of 1440 kkal/day was given. Patient was consulted 
with surgeon and absess was incised and drainage. 
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The operation was uneventful and patient went home 
with mesalazine 3 x 500 mg, methylprednisolone 2 x 4 
mg, rebamipide 3 x 100 mg, iron supplement 1 x 1 and 
folic acid 2 x 5 mg.  He came back to us one week later 
and his symptoms was getting better with complained 
of diarrhea around 1-2 times a day. Reevaluation of 
therapy was planned to be performed after one week.
DISCUSSION
This case report present a case of male young 
adult with IBD. It took two months until the patient 
was diagnosed with IBD. This is probably due to 
unfamiliarity of IBD in Indonesia. The diagnosis of 
IBD is achieved by combining clinical, laboratory, 
endoscopic, histological, and radiological findings.4 
Autoimmune are widely considered as the cause 
of IBD, as most patient with IBD has a individual 
or family history of vasculitis or systemic lupus 
erythematosus.2 Nevertheless, recent studies stated that 
IBD resulted from combination of genetic susceptibility, 
environmental exposure and dysregulated response to 
intestinal microbiota.1,2 In this case, the patient did not 
have an individual nor family history of autoimmune 
disease, but IBD should still be considered as it could 
be result from combination of genetic and environment.
Inflammatory bowel disease can present as bloody 
diarrhea, vague abdominal pain, diarrhea, unexplained 
anemia, fever, weight loss, or growth retardation, 
with bloody diarrhea as the most common presenting 
symptom in UC (in 50% patient).5 In this patient, 
patient came with chronic diarrhea, abdominal pain, 
mild nausea, weight loss with perianal abscess. Perianal 
disease (PAD) in IBD has always been linked to CD 
and can be present in 26% of CD patients.6 Contrary 
to that, recent study by Yabana et al. stated that around 
5% patient with UC may develop PAD and suggest 
that UC patient with PAD should be given steroid, 
because PAD indicating more severe or persistant 
rectal inflammation.6 Extraintestinal manifestation 
of IBD can affect joint, skin, eyes, such as peripheral 
arthritis, erythema nodosum, and episcleritis.7 Patient 
didn’t complain of extraintestinal manifestation and 
this is probably due to according to Levine et al, 
extraintestinal manifestations may present at diagnosis 
only in 6% to 23% of children with a higher frequency 
in those  more than six years.5 
Multiple laboratory tests may be abnormal in IBD. 
These patient usually have decreased hemoglobin 
or elevated total white cell count and platelet count, 
and high inflammatory markers, such as CRP and 
ESR that reflect systemic patient responses.4,5 Patient 
usually has low serum albumin that indicate protein 
losing enteropathy.5 This patient has microcytic 
hypochromic anemia, leukocytosis and thrombocytosis 
with high ESR and CRP. Other than that, patient also 
has hipoalbuminemia. All of these findings fit the 
description of laboratory test in IBD patients.
Revised Porto Criteria for the Diagnosis of 
Inflammatory Bowel Disease in Children and 
Figure 1. Colonoscopy (a,b,c,d,e,f: ulcerative colitis; g,h: perianal abcess; i: internal hemorrhoid)
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Adolescents stated that fecal calprotectin is a more 
sensitive tool for diagnosis of IBD than inflammatory 
markers such as CRP and ESR.5 Calprotectin is a 
calcium and zinc binding protein mostly derived from 
neutrophils and monocytes.4 It has been shown to be a 
reliable marker for assessing IBD disease activity and 
in predicting mucosal healing and risk of relapse.8 In 
this patient, his fecal calprotectin is very high ( > 2100 
(< 50)) that stated there is intestinal inflammation.5 
Stool analysis revealed sign of gastrointestinal 
infection with occult blood test positive, that fit the 
description of IBD.
In recent years, Ileocolonoscopy (and biopsies) 
is the most essential part of the diagnostic workup in 
pediatric IBD and essential in differentiating UC from 
CD.4,5,9 The most reliable feature to diagnose UC is 
continuous mucosal inflammation of the colon, starting 
from the rectum, without small bowel involvement, 
and without granulomas on biopsy.5 Colonoscopy 
in this patient showed perianal abscess with internal 
hemmorhoid grade I-II, hyperemia, erosion and 
superficial ulcers in most mucosal parts of rectum to 
caecum, mucosa of ileum terminalis appears normal 
with conclusion of suggestive ulcerative colitis. 
Colon biopsy revealed irregular superficial 
epithelium with multiple erosive and ulcerative tissue, 
hyperemic lamina propria with multiple chronic and 
acute inflammatory cells, distorted crypts and multiple 
crypt abscess, which disclosed as active chronic colitis 
with crypt destruction and no sign of malignancy. 
Disturbed crypt architecture, cryptitis and crypt abscess 
are signs of chronicity.5 
In a country with tuberculosis is endemic, 
possibility of intestinal tuberculosis (ITB) should be 
considered. ITB and IBD are chronic granulomatous 
disorders with phenotypic similarities that make the 
differentiation between them a challenging task. ITB 
is characterized by numerous large, well-defined 
granulomas, especially in the submucosa and in 
the granulation tissue around the ulcers, often with 
casseation and confluence. TB granulomas has more 
than four sites of granulomatous inflammation per site, 
caseation and a band of epitheloid histiocytes in ulcer 
bases and location of granulomas in the caecum. The 
granuloma in IBD are fewer, smaller, never confluent 
or caseating and seldom found in the submucosa.10
Other modalities that can be used is ultrasound. 
Ultrasound detects, locates, and characterizes 
inflammation of the bowel wall and assesses peri-
intestinal abnormalities, with a good negative 
predictive value for IBD.5 Magnetic resonance imaging 
(MRI) can estimate both the extent of intestinal 
inflammation and the degree of damage (stricturing 
or penetrating disease).5 
Medication and surgery could be used in managing 
IBD.8 Generally, a step-up approach, in which a 
conventional therapy is added if first-line treatment 
is ineffective, has been preferred for many years.8 
However, studies have shown that a top-down 
approach, in which a potent agent is started at the 
early stage of the disease, may be associated with 
reduced hospitalization and surgeries in IBD patients. 
5-Aminosalicylic Acid (5-ASA/Mesalazine) are first-
line treatment for the induction and maintenance of 
remission in mild to moderate UC.8
 Corticosteroid is effective in acute patient.8 
Corticosteroid oral such as prednisone and 
methylprednisolone or corticosteroid enema should 
be given. In severe case, corticosteroid parenteral 
should be given. Budesonide orally or enema is a non-
systemic glucocorticoid that have minimal systemic 
effect with high concentration in intestinal that could 
be used. Mean dosage use until remission is achieved 
is usually 40-60 mg prednisone with tapering dose after 
remission achieved in 8 to 12 weeks.11
Immune-modifying agents such as 6-mercaptopurine 
or azathioprine is used in approximately 6% of cases, 
with only 1% of patients receiving methotrexate.8 
This low use of immune-modifying agents is likely 
to be due to the risk of severe adverse effects and 
the requirements for blood test monitoring.8 Known 
adverse events of this medication include leucopenia 
and transaminases increase, allergic reactions, mild 
(nausea and dyspepsia) or severe (acute pancreatitis) 
gastrointestinal adverse effects, increased risk of or 
non-melanoma skin cancer.8 
Rebamipide is an amino acid derivative of 2 
(1H)-guinoinone that is a gastric mucosal protective 
and ulcer-healing agent. Rebamipide is proven to 
be useful and safe in patient with IBD especially 
in corticosteroid-refractory patient.12 Furuta et al 
conducted  a clinical trial with 21 patient with IBD. 
It was found that rectal administration of rebamipide 
twice a day for 3 weeks led to clinical remission for 
53% patient with no side effect. This is due to anti-
inflammatory activity that rebamipide has.13 Other than 
that, rebamipide healed intestinal injury by enchancing 
the migration of intestinal epithelial cells.14
Patient was given mesalazine and corticosteroid with 
other supportive treatment and showed positive effect. 
The international consensus group recommended that 
disease activity be reassessed at three to six after the 
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start of therapy in UC with colonoscopy.9 Spiceland 
stated that patients with IBD have an increased risk of 
developing colorectal cancer compared to the general 
population, therefore, surveillance endoscopy has been 
recommended in patients with IBD beginning eight 
years after diagnosis.9 
Inflammatory bowel disease should always be 
considered in patient with chronic diarrhea with or 
without extraintestinal manifestation especially after 
poor response of usual antidiarrheal medication. 
Ileocolonoscopy and biopsy is the most accurate 
diagnostic modality for IBD with other helpful 
modalities such as laboratory, stool and imaging 
test. Treatment of IBD are drugs such as mesalazine 
until surgery based on the severity or complication of 
disease.
ACKNOWLEDGEMENT
The author would like to thank Kandi Chandra 
from Department of Gastronterology Siloam Hospitals 
Kebon Jeruk for performing colonoscopy and Welly 
Hartono from Department of Pathology Anatomy 
Siloam Hospitals Kebon Jeruk for analyzing colon 
biopsy result.
REFERENCES
1.  Ng WK, Wong SH, Ng SC. Changing epidemiological trends 
of inflammatory bowel disease in Asia. Intest Res 2016;14:111. 
2.  Yu Y, Zhu S, Li P, Min L, Zhang S. Helicobacter pylori 
infection and inflammatory bowel disease: a crosstalk between 
upper and lower digestive tract. Cell Death Dis 2018;9:961.
3.  Wong S-Y, Cadwell K. There was collusion: Microbes in 
inflammatory bowel disease. Evans MJ, editor. PLOS Pathog 
2018;14:e1007215. 
4.  Rokkas T, Portincasa P, Koutroubakis IE. Fecal Calprotectin in 
Assessing Inflammatory Bowel Disease Endoscopic Activity: 
A Diagnostic Accuracy Meta-analysis. J Gastrointestin Liver 
Dis 2018;27:299-306. 
5.  Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de 
Ridder L, et al. The ESPGHAN Revised Porto Criteria for the 
Diagnosis of Inflammatory Bowel Disease in Children and 
Adolescents: J Pediatr Gastroenterol Nutr 2014;58:795-806.
6.  Zabana Y, Domselaar M, Gracia-Planella E, Manosa M, 
Roman AL, Gordillo J, et al. Perianal disease in patients 
with ulcerative colitis: A case-control study. J Crohns Colitis 
2011;5:338-41. 
7.  Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini 
A, Rogler G. Extraintestinal Manifestations of Inflammatory 
Bowel Disease: Inflamm Bowel Dis 2015;21:1982-92. 
8.  Arnott I, Rogler G, Halfvarson J. The Management of 
Inflammatory Bowel Disease in Elderly: Current Evidence 
and Future Perspectives. Inflamm Intest Dis 2017;2:189-99. 
9.  Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel 
disease: Role in diagnosis, management, and treatment. World 
J Gastroenterol 2018;24:4014-20. 
10.  Navaneethan U, Cherian J, Prabhu R, Venkataraman J. 
Distinguishing tuberculosis and Crohn′s disease in developing 
countries: How certain can you be of the diagnosis? Saudi J 
Gastroenterol 2009;15:142. 
11.  Djojongrat D. Inflammatory Bowel Disease: Alur Diagnosis 
and Pengobatannya di Indonesia. In: Buku Ajar Ilmu Penyakit 
Dalam. 5th ed. Jakarta: Interna Publ.p.591–7. 
12.  Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal 
protective drug with pleiotropic activities. Expert Rev 
Gastroenterol Hepatol 2010;4:261–70. 
13.  Furuta R, Ando T, Watanabe O, Maeda O, Ishiguro K, Ina K, 
et al. Rebamipide enema therapy as a treatment for patients 
with active distal ulcerative colitis. J Gastroenterol Hepatol 
2007;22:261–7. 
14.  Takagi T. Rebamipide promotes healing of colonic ulceration 
through enhanced epithelial restitution. World J Gastroenterol 
2011;17:3802. 
